Plain-English translation of NCT07296341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called HRS-4642, given together with other cancer-fighting drugs, in people with advanced pancreatic cancer that cannot be surgically removed. Researchers want to learn whether this medication combination is safe and whether it helps shrink tumors or slow cancer growth. About 60 people with pancreatic cancer will participate at multiple medical centers.
Pancreatic cancer is very difficult to treat, especially when it has spread or cannot be removed with surgery. Doctors are looking for better treatment combinations that could help patients live longer and feel better, which is why they are studying whether adding this medication to standard treatments makes them more effective.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication HRS-4642 combined with other standard cancer drugs (either Adebrelimab Injection with nab-paclitaxel and gemcitabine, or just nab-paclitaxel and gemcitabine, depending on which group you are randomly assigned to). You will visit the study center regularly for treatment and monitoring, including blood tests and imaging scans to check how well the treatment is working and watch for side effects. The study will track your health over time to understand whether this medication combination is safe and effective.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China